Home
|

Isobologram analysis

The benefit of combined therapies are being realised in the clinic. This has opened the door to a plethora of drug combinations being developed particularly for patients refractory to therapy. Resistant tumours may also be susceptible to combination therapies.

Whether or not a given drug combination works synergistically can be determined by isobologram analysis of data obtained from growth inhibition assays. The Loeweadditivity model (isobologram) is the most appropriate analysis for evaluating whether drugs are synergistic in their ability to kill tumour cells.

 

Drugs that are given in combination may produce effects that are greater than or less than the effect predicted from their individual potencies. The historical basis for predicting the effect of a combination is based on the concept of dose equivalence; i.e., an equally effective dose (A) of one will add to the dose (B) of the other in the combination situation. For drugs with a constant relative potency, this leads to linear additive isoboles (A–B )curves of constant effect (line of additivity), whereas a varying potency ratio produces non-linear additive isoboles. Determination of the additive isobole is a necessary procedure for assessing both synergistic and antagonistic interactions of the combination.

Through utilization of these analyses the optimal combination can be determined.

SERVICES
Drug Development Solutions
Hits to optimised leads
Lab Based Due Diligence
Customised Assay Development
Anticancer Drug Development
> Lead Selection Studies
> Efficacy Studies
> Isobologram Analysis
> Transcription profiling
Human Risk Assesment
Collaborative Research
 

© Copyright CXR Biosciences Scotland 2007 | James Lindsay Place, Dundee Technopole, Dundee, Scotland DD1 5JJ Tel +44 1382 432163
Web Design, Development and hosting by MTC Media